

NeuroAudit Proposal

Intelligent Patch Driving Instant Cognitive Boost



Who Are We? Introduction



Most innovative Neurotechnology company of 2022



Neurotechnology innovation specialists of 2022



Multidisciplinary project Founded in 2019

学際的プロジェクト 2019年設立



Developed an innovative Psychoacoustic Neurotech


音響心理技術「Psychoacoustic Neurotech」の開発




Intelligent patch driving an instant cognitive boost in Alzheimer's disease アルツハイマー病の認知機能を高めるインテリジェント・パッチ・ドライブを開発




World's Alzheimer's population Market Challenge



The world's older population is more likely to develop Alzheimer's disease and dementia, which are associated with cognitive disorders.



The Number of people with dementia is predicted to grow up to 152,000,000 by 2050



Estimated growth in number of people with dementia 2020–2050


2030

2050

2020



Alzheimer's Market Costs Alzheimer's Diseases effects



Mortality

1 of 3 people suffering from Alzheimer's will die from Alzheimer's or dementia.

Its mortality rates are more than those of breast cancer and prostate cancer

アルツハイマー病患者の3人に1人は、アルツハイマ ー病または認知症で死亡すると言われている。死亡 率は、乳がんや前立腺がんの合計よりも高い。

An estimate of 6.2 Million Americans aged 65 and older live with Alzheimer's or dementia in 2021. (**72% percent are age 75 or**

2021年には、65歳以上のアメリカ人推定 620万人がアルツハイマー病や認知症とな なっている(そのうち72%は75歳以上)


66% of caregivers live with a person with dementia in the community

有病率 介護者の66%が認知症の方と同居している

Quick **Facts** ファクト

COSTS COULD RISE AS HIGH **AS \$1.1 TRILLIO**IN 2021, ALZHEIMER'S WILL COST THE NATION \$355 BILLION. BY 2050, THESE N.

MORE THAN 11 MILLION AMERICANS PROVIDE UNPAID CARE FOR PEOPLE WITH ALZHEIMER'S IN 2020. THESE CAREGIVERS PROVIDED AN ESTIMATED 15.3 BILLION HOURS OF CARE VALUED AT NEARLY \$257 BILLION.





Alzheimer's Gov Programs

Finding Treatment Proposition

Over the Globe, more than 377 National programs are working with Academic institutions and governments to find treatment for Alzheimer's disease

世界では、377以上の国家プログラムが、学術機関や政府と協力してアルツハイマー病の治療法を探している






Product Value Proposition


NeuroAudit Product

- Clinical technology, innovative brain stimulation via Blood conduction
- The smallest Ultrasound device available
- Based on LFUS (Low-Frequency Ultrasound Stimulus)
- Creating instant cognitive boost
- User-friendly, suitable for daily use in home














Value Proposition

What Does it Mean?



Innovation



Cognitive boost for patients suffering from Alzheimer's, cognitive.



Using a novel blood conduction technic to transfer the stimulation to the brain via the carotid artery,



Using a psychoacoustics ultrasound neuro-stimuli, which is field that explores the effects of ultrasound on the brain.

Market Impact





Large and growing market of neurological disorders, which affect millions of people worldwide.



Affordable, user-friendly, suitable for Alzheimer's.



A competitive edge intelligent daily-use patch.

Vision





Establishing strong relationships with the Alzheimer's market and Alzheimer's patient.



Initial target customers **are large**Pharma Networks, potential dealers
and local pharma networks.



Total addressable market for our product will be approximately \$500 million per year.



Case Studies POC's Timeline



Results:

More than 70% of cognitive performance was CORRELATED with less left-brain activity effort

70%以上の認知パフォーマンスは、左脳の活動努力が多ないことと相関していた

2020

Japan POC cognitive performance 日本におけるPoC 認知パフォーマンス



2016tDCS Preliminary POC Detecting Signal effect tDCS予備的POC



2017

ADHD Preliminary POC Detecting Cognitive Gaps ADHD予備的POC 認知機能のギャップを発見




2019

E.M.G Preliminary POC Detecting Ultrasonic Effect E.M.G 予備的POC 超音波効果の検出



2019

ADHD-2 Preliminary POC **Detecting Cognitive**ADHD予備的POC
認知検知







2016

Ronen deaf test
Detecting Ultrasonic signal
聴覚障害者テスト



2018

Sonic Preliminary POC
Detecting Cognitive Gaps
ソニック予備的POC
認知ギャップ検知



2019

US Stimulate POC Brain Ultrasonic Response 脳内超音波応答

Results:

More than 70% cognitive performance was CORRELATED with less left-brain activity effort

結果:


70%以上の認知パフォーマンスは、左脳の活動努力が少ないことと相関していた



Japan POC (13 Dec. 2019)


Publications based on Ultrasound Neurostimulation

- > Test case POC with Astem company from Japan (KGAP+ Batch1)
- > Technology knowledge exchange & results based on Innovative two Brain
- > Technology integration (Ultrasound Brain Technology & NIR Brain Technology).
- ► 日本のアステム社とのテストケースPOC(KGAP+ Batch1)
- > 革新的な2つの脳技術統合に基づく技術知識の交換と成果
- ▶ 技術知識の交換と成果(超音波ブレインテクノロジーとNIRブレインテクノロジー)



Right Brain

- Emotional
- Intelligence
- Experiences



Left Brain

- language
- logic
- analytical
















NeuroAudit Brain Technology (Ultrasonic brain stimulation)



Stroop effect interference (Cognitive

- Ultrasound & NIR Working without artifacts interference
- NeuroAudit stimulation influences performance on Cognitive task

diagnostic)

- Astem NIR System can measure influence with NeuroAudit stimulation.
- Cognitive performance enhancement was shown along the stimulating correlated less brain effort in the left Brain (ADHD)




Supporting Clinical and Publications

Publications based on Ultrasound Neurostimulation

An Supersound to clean up the brain

Microbubbles injected into the blood vibrate under ultrasound, temporarily forcing cells lining the blood-brain barrier apart. This may allow amyloid-fighting antibodies to slip into brain tissue (shown) or rouse cells that clean up the protein.



TO EUREKAIER!

MAAAS

SEARCH ARCHIVE

Q

ADVANCED SEARCH

HOME NEWS RELEASES MULTIMEDIA MEETINGS

LOGIN REGISTER

NEWS RELEASE 24-JAN-2022

Researchers from the GIST propose ultrasound stimulation as an effective therapy for Alzheimer's disease in nev study

Synchronizing one's brainwaves to ultrasound pulses could reduce the accumulation o abnormal proteins characteristic of the onset of Alzheimer's disease

Peer-Reviewed Publication

GIST (GWANGJU INSTITUTE OF SCIENCE AND TECHNOLOGY)

Print Remail App

SEARCH ARCHIVE

Q

ADVANCED SEARCH

LOGIN REGISTER

bilonas Ismathal

Violation

Bilonas Ismathal

Violation

Semall App

Print Remail App

Violation

Dilonas Ismathal

Violation

Dilonas Ismathal

Dilona

With the increase in average life expectancy in many parts of the world, certain agerelated diseases have become more common. Alzheimer's disease (AD), unfortunately, is one of them, being extremely prevalent within aging societies in Japan, Korea, and various European countries. Currently there is no cure or an effective strategy to slow down the progression of AD. As a result, it causes much suffering to patients, families, and caregivers as well as a massive economic burden.

Fortunately, a recent study by a team of scientists at the Gwangju Institute of Science and Technology (GIST) in Korea has just demonstrated that there might be a way to combat AD by using ultrasound-

way to combat AD by using" ultrasoundbased gamma entrainment," a technique that involves syncing up a person's (or an animal's) brain waves above 30 Hz (called "gamma waves") with an external oscillation of a given frequency. The process happens naturally by exposing a subject to a repetitive stimulus, such as sound, light, or mechanical vibrations.

Previous studies on mice have shown that gamma entrainment could fight off the formation



Carotid Artery

IMAGE: ULTRASOUND STIMULATION AS AN EFFECTIVE THERAPY FOR ALZHEIMER'S DISEASE view more >

CREDIT: GWANGJU INSTITUTE OF SCIENCE AND TECHNOLOGY



Supporting Clinical and Publications

Publications based on Ultrasound Neurostimulation

Journal of Neurodegenerative Diseases and Disorders




Abstract

Non-invasive apparatus and method for Cranial Brain Stimulation

Ultrasound (US) has received widespread attention as an emerging technology for targeted, non-invasive neuromodulation based on its ability to evoke electro-physiological and motor response As the focusing is achieved through constructive interference of the incident waves, a focal spot can be formed at depth within the tissue without affecting cells along the propagation path closer to the transducer.

Hearing is a well-known sensory phenomenon that enables humans to hear sounds at a far higher frequency than would naturally be detectable through the actual inner ear, typically by stimulation of the cochlea base by bone conduction.

Author(s): Dan Anzyo Abstract | PDF





Following on from your recent nomination in Global Health & Pharma's seventh annual Biotechnology Awards, I am delighted to be reaching out to inform you that NeuroAudit has been successful in this years' edition, and has been awarded:




Most Innovative Neurotechnology Company
- Middle East -



Global Activities

Global



Japan activities



US activities



Brazil activities





Product Roadmap

Timeline to GTM

Business model

- > Recurrent Revenue
- Initial customers Pharma companies & potential dealers
- > 2nd B2B customers mid/local area pharma networks

Invest in Intelligent Neurotech

2023 FDA approval

Seed funding

2022

т БА аррго

2020 MVP ready

2023 Clinical **2024**Go to
market

Investment traction

- > Huge market Alzheimer's in the US will double to 13 million
- > Technology is ready for the Market
- > Innovative, simple to use, No services
- Disrupting Technology



Investment Roadmap- Full Partnership

- > First millstone 9 months
- > Second millstone 14 months
- > Grow millstone 18 months
- > Milestone timeline 18 \ 14 \ 9 months






Alzheimer's Market Plan

Alzheimer's Diseases market effects

GTM using Neuro Audit Patch as a standards-home care for daily use product





POCs completed

Product cognition boost demo completed

Company assets include FDA approval and additional applications in process

Partner and customer ecosystems initiated and several pilots in deployment





Key Investment Thesis



Full worldwide Partnership

Dan Anzio CEO & Business Development

Leads the management and strategy of NeuroAudit, experienced in marketing & technology development with a blend of business acumen and implementing marketing plans to maximize results and bring to the table a strategic view, high analytical skills, leading to result in business growth and personal empowerment



Rachel Langford, MSc.Med, Clinical Science

Heads the Research at NeuroAudit. Neuroscientist and a clinician in private brain assessment and training clinics using HEG NIRS and EEG technology for improving brain functions. Her previous research fields were in medical neuroscience and health psychology.



Erez Saadon CTO & R&D Designer

Heads the R&D Technology Research at NeuroAudit. Responsible for researching the bi-lateral development Technology interaction Is areas for many years as an electronical, software engineer

Leadership

Team



Dr. Boaz Sadeh Clinical Science Advisory board

R&D clinical science, computational neuroscientist, and electrophysiologist. Served as lead neuroscience and researcher in the medical device industry and has more than 15 years of research experience working with EEG, functional MRI, and transcranial magnetic stimulation (TMS)



Dr. Lionel Krief MD Advisory board

Medical expert with a specialty in nuclear medicine. Has diagnosed Alzheimer's Disease in the EU for over 20 years, specializing in nuclear medicine and PET (two imaging modalities used to examine organ function)



Dr. Alon Sinai Clinical Science Advisory board

Neurophysiologist in the department of neurosurgery at Rambam Medical Center, Haifa. Was a research fellow at Johns Hopkins University, Baltimore, Maryland (2003-2008). Specialized in evoked potentials, electrophysiology, and methods of electrical and magnetic stimulation for the treatment of various disabilities in the nervous system



Esther Fuerster-Askhenazi, Clinical programs

Many years in the field of forensic genealogy; assisted a governmental agency to build their research system in Poland, and Eastern Europe; increasing their response rate. Has close ties with governmental and nongovernmental organizations in Israel and around the world.

Invest in the future of Humanity with us NeuroAudit



